-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

602.O2.6 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Altered Transcription Factor Regulation

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
HSCs, Adult, AML, iPSCs, Animal models, Diseases, cell division, cell regulation, Elderly, MDS, cellular interactions, Biological Processes, white blood cells, Young Adult, Technology and Procedures, Cell Lineage, Xenograft models, epigenetics, Study Population, Myeloid Malignancies, genomics, hematopoiesis, flow cytometry, integrative -omics, NGS, molecular interactions, pathogenesis, pathways
Sunday, December 6, 2020: 2:00 PM-3:30 PM
Moderators:
Kathrin M. Bernt, MD, Children's Hospital of Philadelphia and Sridhar Rao, MD, PhD, Blood Center of Wisconsin
Disclosures:
Bernt: Syndax: Research Funding; Agios: Consultancy; Merck: Other: Husband works for Merck.
2:00 PM

Maria M. Aivalioti, BS1*, Tushar D Bhagat, PhD2,3*, Aditi Paranjpe, MS.4*, Boris Bartholdy, PhD1*, Kith Pradhan, PhD5*, Mario Pujato, PhD4*, Amit Verma, MBBS2,3 and Britta Will, PhD1,3*

1Department of Cell Biology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY
2Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY
3Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY
4Bioinformatics Collaborative Services, Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
5Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

2:15 PM

Emiel Van Der Kouwe1*, Gerwin Heller, PhD2*, Akos Czibere, MD3*, Lucio H. Castilla, PhD4, Ruud Delwel, PhD5, Annalisa Di Ruscio, MD, PhD6, Alexander Ebralidze, PhD7*, Maurizio Forte, MSc1*, Lukas Kazianka, MD1*, Christoph Kornauth8*, Trang Le, BSc1*, Karin Lind, MSc9*, Ines Barbosa, PhD10*, Alexander Pichler, MD1*, John Pulikkan, PhD11*, Ann-Sofie Schmolke, MD1*, Heinz Sill, MD9*, Wolfgang R. Sperr, MD1*, Andreas Spittler, MD12*, Bon Q. Trinh, PhD6*, Peter Valent, MD13, Katrina Vanura, PhD1, Robert Welner, PhD14, Johannes Zuber, PhD10*, Daniel G. Tenen, MD6,15 and Philipp B. Staber, MD, PhD16

1Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
2Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
3Pfizer Inc., Cambridge, MA
4UMass Medical School, Worcester, MA
5Erasmus MC, Rotterdam, Netherlands
6Harvard Medical School, Boston, MA
7Harvard Stem Cell Institute, Harvard Medical School, Boston
8Department of Medicine I, Division of Hematology, Medical University of Vienna, Wien, Austria
9Department of Internal Medicine, Division of Hematology, Medical University of Graz, Graz, Austria
10Research Institute of Molecular Pathology (IMP), Vienna, Austria
11Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI
12Core Facility Flow Cytometry and Surgical Research Laboratories, Medical University of Vienna, Vienna, Austria
13Department of Medicine I, Division of Hematology, Medical University of Vienna, Vienna, Austria
14Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL
15Cancer Science Institute of Singapore, Singapore, Singapore
16Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University Vienna, Vienna, Austria

2:30 PM

Gabriela Krivdova, BSc1,2, Veronique Voisin, PhD3*, Sajid Marhon4*, Schoof E Erwin4*, Martino Gabra5*, Jessica L. McLeod6*, Leonardo Salmena7*, Mark D. Minden8, Eric R. Lechman,, PhD1 and John E. Dick, PhD, FRS6,9

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Molecular Genetics, University of Toronto, Toronto, ON, Canada
3Terrence Donnelly Centre for Cellular and Biomedical Research, University of Toronto, Toronto, ON, Canada
4University Health Network, Toronto, Canada
5Pharmacology, University of Toronto, Tornto, Canada
6Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada
7Pharmacology, University of Toronto, Toronto, Canada
8Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
9Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

2:45 PM

Sapana S Jalnapurkar, PhD1, Aishwarya Pawar1*, Patrick Somers1*, Gabrielle Ochoco1*, Subin S George1*, Maxim Pimkin, MD, PhD2,3 and Vikram R Paralkar, MD1

1Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA
2Broad Institute of MIT and Harvard, Cambridge, MA
3Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Brookline, MA

3:00 PM

Pavithra Shyamsunder1,2*, Shree Pooja Sridharan1*, Pushkar Dakle1*, Zeya Cao1,3*, Vikas Madan, PhD1*, Sin Tiong Ong, MD2,4 and H. Phillip Koeffler, MD1,5,6

1Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
2Cancer & Stem Cell Biology Programme, DUKE-NUS Medical School, Singapore, Singapore
3Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
4Department of Medicine, Duke University Medical Center, Durham, NC
5Cedars-Sinai Medical Center, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA
6Department of Hematology-Oncology, National University Cancer Institute of Singapore (NCIS), National University Hospital, Singapore, Singapore

3:15 PM

Brahim Arkoun1,2*, Virginie Dufour3*, Aurélie Siret4*, Stefania Mazzi1*, Yasmine Mammasse3*, Mathieu Vieira1*, Fabien Boudia4*, Elie Robert4*, Zakia Aid4*, Marie Cambot3*, Rachel Petermann3*, Sylvie Souquere5*, Philippe Rameau6*, Cyril Catelain6*, Romain Diot7*, Gérard Tachdjian7*, Najet Debili1*, Isabelle Plo1,2*, Hana Raslova1*, Sebastien Malinge4,8*, Eric Soler9*, Thomas Mercher4* and William Vainchenker1,2,3*

1INSERM, UMR1287, Gustave Roussy, Université Paris-Saclay, Equipe labellisée Ligue Nationale Contre le Cancer, Equipe GRex, Villejuif, France
2Laboratory of Excellence GReX, Paris, France
3Institut National de la Transfusion Sanguine (INTS), Department of Platelet Immunology, F-75739, Paris, France
4INSERM, UMR1170, Gustave Roussy, Université Paris-Saclay, Equipe labellisée Ligue Nationale Contre le Cancer, Villejuif, France
5Centre National de La Recherche Scientifique, UMR-8122, Gustave Roussy, Villejuif, France
6INSERM US23 AMMICA, Gustave Roussy, Université Paris-Saclay, Villejuif, France
7Assistance Publique-Hôpitaux de Paris Service d'Histologie, Embryologie et Cytogénétique, Université Paris-Saclay, Hôpital Antoine Béclère, Clamart, France
8Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia., Perth, Australia
9Institut de Génétique Moléculaire de Montpellier, Univ Montpellier, CNRS., Montpellier, France

*signifies non-member of ASH